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A B S T R A C T   
Here we describe the generation of induced pluripotent stem cell lines from each member - male proband, mother, father - of a schizophrenia case-parent trio that 
participated in an exome sequencing study, and 3 de novo mutations were identified in the proband. Peripheral blood mononuclear cells were obtained from all three 
individuals and reprogrammed using Sendai virus particles carrying the Yamanaka transgenes. These 3 iPSC lines (iPSC-SZ-HU-MO 1, iPSC-SZ-HU-FA 1, and iPSC-SZ- 
HU-PROB 1) represent a resource for examining the functional significance of the identified de novo mutations in the molecular pathophysiology of schizophrenia.   
1. Resource Table  





Alternative names of stem 
cell lines 
iPSC-SZ-HU-PROB 1 
iPSC- SZ-HU-MO 1 
iPSC-SZ-HU-FA 1 
Institution 1. Molecular Psychiatry Research Group, National Brain 
Research Program (NAP), Hungarian Academy of 
Sciences and Semmelweis University 
2. Institute of Enzymology, Research Center for Natural 
Sciences, Eötvös Loránd Research Network 
Contact information of 
distributor 
Ágota Apáti, apati.agota@ttk.mta.hu 
János M. Réthelyi, rethelyi.janos@med.semmelweis- 
univ.hu 
Type of cell lines iPSC lines 
Origin human 




Sendai virus reprogramming 
Multiline rationale iPSCs derived from a case-parent trio 
Gene modification Yes 
Type of modification de novo mutations in proband 
Associated disease Schizophrenia 
(continued on next column)  
(continued ) 









Method of modification NA 






Date archived/stock date June 15, 2015 
Cell line repository/bank NA 
Ethical approval Health Care Research Council, Human Reproduction 
Committee in Hungary (in Hungarian: Egészségügyi 
Tudományos Tanács, Humán Reprodukciós Bizottság, 
ETT HRB) 
Approval number: 33873-3/2014-EHR  
2. Resource utility 
De novo mutations (DNMs) have been implicated in the etiology of 
schizophrenia (SZ), a chronic psychiatric disorder characterized by 
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severe symptoms and impaired community functioning. By generating 
iPSC lines from patients carrying DNMs and using neuronal differenti-
ation we can investigate directly the biological significance of DNMs 
(Tables 1 and 2). 
3. Resource details 
Schizophrenia is a chronic debilitating psychiatric disorder charac-
terized by diverse clinical symptoms, i.e. hallucinations, delusions, so-
cial withdrawal, neurocognitive dysfunction, and as a consequence of 
these, decreased educational and workplace functioning (van Os and 
Kapur, 2009). Strong genetic effects and corresponding levels of heri-
tability have been demonstrated in genetic studies of schizophrenia, 
however the emerging genetic architecture is complex, implicating a 
role for both common and rare genetic variants. The polygenic effect of 
common variants, i.e. single nucleotide polymorphisms, have been 
shown in genome-wide association studies. Rare variants such as copy 
number variants (CNVs) and DNMs are present in a small proportion of 
schizophrenia patients, however the associated risk is higher for these 
variants. The large scale identification of disruptive DNMs in schizo-
phrenia has become feasible with the advent of next generation 
sequencing, whole exome and genome sequencing (Takata et al., 2016). 
While several DNMs have been demonstrated by examining schizo-
phrenia cases and their unaffected parents, and DNMs can be evaluated 
using the predictions of bioinformatics tools with regard to their disease- 
causing effects, in most cases their biological significance remains 
inconclusive. iPSC-based in vitro disease modelling has been exploited 
successfully to elucidate the molecular disease pathways giving rise to 
schizophrenia (Brennand et al., 2011). Therefore it is plausible to use 
this model system for the investigation of disruptive DNMs in 
schizophrenia. 
Here we describe the generation of iPSCs from a schizophrenia case- 
patient trio, in which the male proband is a carrier of 3 nonsynonymous 
DNMs in genes leucine rich repeat containing 7 (LRRC7), KH-Type 
Splicing Regulatory Protein (KHSRP), and Killer Cell Immunoglobulin- 
Like Receptor, Two Domains, Long Cytoplasmic Tail, 1 (KIR2DL1). 
iPSC lines were generated from the patient’s and parents’ peripheral 
blood mononuclear cells using Sendai virus-based reprogramming. 
iPSCs were investigated and characterized using brightfield microscopy 
(Fig. 1A upper panel) and alkaline phosphatase staining (Fig. 2A upper 
panel), immunocytochemistry (Fig. 1A middle panel), flow cytometry 
(Fig. 1A lower panel and Fig. 2A), qPCR (Fig. 1B), and karyotyping 
(Fig. 1C). These assays confirmed the pluripotency and genomic integ-
rity of the generated iPSCs. Virus clearance was monitored using qPCR 
(Fig. 1B). Spontaneous differentiation experiments demonstrated the 
expression of multiple germline markers, thus confirming that the iPSC 
lines are able to differentiate into all three germ layers (Fig. 1D and 
Fig. 2B). The DNMs were validated in the iPSC lines by resequencing the 
genomic loci of interest (Fig. 1E). Rigorous characterization and quality 
control has indicated the pluripotency and genomic integrity of the 
derived iPSC clones (Fig. 1 and Fig. 2). The significance of these cell lines 
lies in their utility for examining the functional role of the DNMs har-
boured in the proband, who is a schizophrenia patient. In subsequent 
experiments, we will seek to identify molecular and cellular phenotypes 
that differ between the progenies of the individual cell lines. As 
schizophrenia is the disorder of the central nervous system, more pre-
cisely of forebrain glutamatergic and GABAergic neurons and their 
network circuitry, we plan to use targeted neuronal differentiation 
protocols to study homogenous neuronal populations in terms of tran-
scriptomics, synaptic connectivity, single-cell electrophysiology and 
calcium signalling. The process of reprogramming case-parent trios 
represents a means for investigating disease-causing mutations by 
Table 1 
Summary of lines.  
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease 
iPSC- SZ-HU-MO 1 iPSC- SZ-HU-MO 1 Female 55 Caucasian 19:6416869CC healthy control 
iPSC-SZ-HU-FA 1 iPSC-SZ-HU-FA 1 Male 59 Caucasian (19:6416869CC healthy control 
iPSC-SZ-HU-PROB 1 iPSC-SZ-HU-PROB 1 Male 24 Caucasian 19:6416869CA schizophrenia patient  
Table 2 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Olympus CKX 41 Normal iPSCs formation Fig. 1 panel A and Fig. 2 
panel A 
Phenotype Qualitative analysis 
AP staining 
Immunocytochemistry 
Positive for pluripotency markers: Oct4, Nanog 
Positive for AP staining 
Fig. 1 panel A 
Quantitative analysis Flow 
cytometry, RT-qPCR 
Cell surface markers: SSEA-4, TRA1-60, and TRA1-81: >90% all of cell lines 
RT-qPCR: Nanog, Brachyury, AFP 
Sendai clearance qPCR: SevFam, cMyc, Klf4, Oct3/4, Sox2 
Fig. 1 panels A, B and  
Fig. 2 panel A. 
Genotype Karyotype (G-banding) and 
resolution 
iPSC- SZ-HU-MO 1:46 XX, iPSC-SZ-HU-FA 1: 46 XY, iPSC-SZ-HU-PROB 1: 46XY 
Resolution: 450–500 bands per haploid chromosome set. 
Fig. 1 panel C 
Identity STR analysis DNA Profiling 
Performed 
Submitted in archive 
with journal 
17 sites tested, all matching between PBMC and iPSC lines. Submitted in archive 
with journal 
Mutation analysis (IF 
APPLICABLE) 
Sequencing IPSC-SZ-HU-PROB 1: heterozygous missense mutation in LRRC7 and KHSRP 
iPSC- SZ-HU-MO 1 
iPSC-SZ-HU-FA 1: homozygous in LRRC7 and KHSRP 
Fig. 1 panel D 
Southern Blot OR WGS NA  
Microbiology and 
virology 
Mycoplasma test by MycoAlert Mycoplasma testing by luminescence 
Negative 
not shown but available 
with author 
Differentiation potential Spontaneous differentiation Immunocytochemistry: iPSCs state: Nanog, Oct4, 
EBs state: SMA, AFP, β-tubulin, NESTIN, BMP4, SOX17 
Fig. 1 panels A, E and  
Fig. 2 panel B. 
Donor screening HIV 1 + 2, Hepatitis B, Hepatitis C Negative not shown but available 
with author 
Genotype additional info Blood group genotyping NA  
HLA tissue typing NA   
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Fig. 1. Characterization and quality control of iPSC clones.  
Fig. 2. Characterization of iPSC clones.  
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comparing multiple cell lines, which share considerable levels of genetic 
background (Wright et al., 2014). This approach to decrease genetic 
heterogeneity could complement the application of genome editing 
technologies used to establish isogenic cell lines that are also emerging 
in the in vitro disease modelling field. 
4. Materials and methods 
4.1. Reprogramming of PBMCs, isolation of iPSC clones and in vitro 
spontaneous differentiation 
Peripheral mononuclear cells (PBMCs) were prepared according to 
manufacturer’s instruction (BD Vacutainer CPT). PBMCs were cultured 
for 4 days with daily medium changes at a density of 5 × 105 cells/ml in 
StemPro®-34 (Thermo Fisher Scientific) medium supplemented with 2 
mM L-Glutamine and cytokines at the following final concentrations 
(SCF 100 ng/mL, FLT-3 100 ng/mL, IL-3 20 ng/mL, IL-6 20 ng/mL, all 
from Peprotech). On day 4, PBMCs were transduced with Sendai virus 
particles carrying KOS (hKlf4, hOct3/4, hSox2), hc-Myc, and hKlf4 at 
MOIs of 5,5, and 3, respectively (according to the Cytotune 2.0 Kit user 
guide (Thermo Fisher Scientific)). Two days after transduction the 
transduced cells were seeded onto mitomycin treated mouse embryonic 
fibroblasts (MEFs) and further propagated until pluripotent clumps 
appeared. Six days after transduction, the culturing medium over the 
cells was gradually changed to KO-DMEM, supplemented with 15% KO 
Serum Replacement (Thermo Fisher Scientific), 100 mM glutamine 
(Thermo Fisher Scientific), 1% nonessential amino acids (Thermo Fisher 
Scientific), 0.1 mM βMercaptoethanol (Thermo Fisher Scientific) and 4 
ng/ml bFGF (Thermo Fisher Scientific). 14–18 days after transduction, 
individual iPSC colonies were mechanically transferred to new MEF to 
generate clones. 
14–18 days after transduction, individual iPSC colonies were me-
chanically transferred to mouse embryonic fibroblasts to generate 
clones. To ensure virus clearance and monitor stability, the clones were 
repeatedly passaged and expanded up to p10 using trypsin. Heat treat-
ment at 38.5 ◦C was used between passage p4-p8 to take advantage of 
the heat sensitivity of virus particles. In vitro spontaneous differentiation 
experiments were performed as described earlier (Erdei et al., 2014). 
Briefly, three confluent wells of iPS colonies maintained on MEF were 
removed using by Collagenase IV and transferred into ULA (Ultra low 
attachment) plates in EB medium (KO-DMEM supplemented with 20% 
FBS, 1 mM L-GLU, 1% non-essential amino acids, and 0,1 mM ß-mer-
captoethanol (Thermofisher Scientific)) to ensure the formation of 
floating Embryoid Bodies (EBs). The medium was changed daily for 6 
days. After 6 days of suspension culture, the EBs were further differen-
tiated on gelatine-coated 8 well confocal chambers for immunofluores-
cence staining in DMEM supplemented with 10% FBS. 
4.2. Alkaline phosphatase assay 
Multiple iPSC clones were tested for alkaline phosphatase enzymatic 
activity using the Alkaline Phosphatase Detection kit (EMD Millipore). 
4.3. Immunocytochemistry 
iPSCs or iPSC-derived EBs were seeded on Matrigel-coated Lab-Tek 
chambers (Thermo Fisher Scientific). 1 days after plating of iPSCs or 6 
days after plating EBs, the samples were fixed using 4% para-
formaldehyde. After blocking and permeabilization with a buffer con-
taining 0.2% BSA, 1% fish gelatine, 3% goat serum, and 0.1% TritonX- 
100, the cultures were incubated with primary antibodies (see Table 3) 
for 1 h. Next, the samples were incubated with secondary antibodies and 
counterstained with DAPI (Sigma). The pictures were taken by ZEISS 
LSM710 confocal laser scanning microscope. 
4.4. Quantitative PCR and virus clearance assay 
RNA was isolated with Trizol (Thermo Fisher Scientific). RNA sam-
ples were reverse transcribed to cDNA using GoScript™ Reverse Tran-
scriptase (Promega). Taqman gene expression assays were used for 
quantification of mRNA expression level of Nanog, AFP, Brachyury, and 
Pax6 relative to that of RPLP0. For monitoring virus clearance, we used 
Table 3 
Reagents details.  
Antibodies used for immunocytochemistry/flow-cytometry  

















AB_628051, Cat.no.: Sc- 
5279, Santa Cruz 
Biotechnology, CA, USA 
AB_355097, Cat.no.: 
AF1997, R&D System 
AB_357038, Cat.no.: 
FAB1435P, R&D Systems 
AB_891610, Cat. 
no.: 14–8863-82, 
eBioscience, MA, USA 
AB_891614, Cat. 
no.: 14–8883-82, 




Mouse anti-B III 
tubulin 
Mouse anti-SMA 






























Alexa Fluor 647- 
conjugated goat 
anti-mouse IgG 
Alexa Fluor 568- 
conjugated goat 
anti-rabbit IgG 






































Cat.no.: 4331182, Hs02387400_g1 
Cat.no.: 4331182, Hs00610080_m1 
Cat.no.: 4331182, Hs00173490_m1 
House-Keeping 
Genes (qPCR) 
RPLP0 Cat.no.: 4331182, 1500979, 
HS99999902_m1 
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the TaqMan IPSC Sendai detection Kit (Thermo Fisher Scientific). 
The PCR reactions were performed following the thermal profile 
below: denaturation at 95◦ C for 10 min, followed by incubation at 95◦ C 
for 15 s, and annealing at 60◦ C for 1 min during 40 cycles, using Step 
One Plus PCR device (Applied Biosystems). 
4.5. Flow cytometry analysis 
Expression of pluripotency marker SSEA4 was assessed by flow 
cytometry (as described previously (Erdei et al., 2014)). Data was 
collected with an Attune Acoustic Focusing Cytometer (Applied Bio-
systems by Life Technologies) and analysed with the Attune Cytometric 
Software. 
Flow cytometry was performed as described previously (Erdei et al., 
2014). SSEA4-PE (R&D Systems, 1:25 dilution), TRA1-60 (eBioscience, 
1:200 dilution) and TRA1-81 (eBioscience, 1:200 dilution) were used for 
investigation of pluripotency while anti-mouse Sca-1 (Ly-6A/E) -APC, 
(eBioscience, 1:25 dilution) antibody was employed for gating out the 
MEF. Isotype-matched control mAbs were used for SSEA4 (IgG3-PE 
(R&D Systems, 1:25 dilution) and for TRA1-60 and TRA1-81 (mouse IgM 
Isotype Control 11E10 (eBioscience, 1:200 dilution). Secondary anti-
body AlexaFluor-488 conjugated goat anti-mouse IgG, IgM (H + L) 
(Invitrogen, 1:250 dilution) was used in the case of TRA1-60 and TRA1- 
81. The cells were incubated with the antibodies for 30 min at 4 ◦C, 
without permeabilization. Before measurements Topro3-iodide (Invi-
trogen, 1:300 dilution) was used for gating the living cells. Data was 
collected with FACSAria III Cell Sorter (BD Biosciences) and analyzed 
with the FCS Express 6 Software. 
4.6. Karyotyping and STR analysis 
Karyotyping and STR analyses were performed by the Cytogenetic 
Laboratory of Semmelweis University and UD-GenoMed Medical 
Genomic Technologies Ltd (Hungary), respectively. Chromosomal ab-
normalities were screened by G-banding analysis of IPSC clones. Kar-
yotypes were described according to the International System for 
Human Cytogenetic Nomenclature (ISCN, 2016). iPSC clones were 
authenticated by STR analysis using GenePrint® 10 System (Promega). 
4.7. Sanger sequencing 
Genomic DNA (gDNA) was isolated from the iPSCs using Quick-DNA 
Miniprep Kit (Zymo Research). For PCR amplification the primers are 
listed in Table 3. Sanger sequencing reactions were carried out with the 
3130 Genetic Analyzer (Applied Biosystems by Life Technologies). 
4.8. Mycoplasma test 
MycoAlertTM Mycoplasma Detection Kit was used according to the 
manufacturer’s instructions (Lonza). 
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Orbán, T.I., Sarkadi, B., Apáti, A., 2014. Expression pattern of the human ABC 
transporters in pluripotent embryonic stem cells and in their derivatives. Cytometry 
B Clin. Cytom. 86 (5), 299–310. 
Takata, A., Ionita-Laza, I., Gogos, J., Xu, B., Karayiorgou, M., 2016. De novo synonymous 
mutations in regulatory elements contribute to the genetic etiology of autism and 
schizophrenia. Neuron 89 (5), 940–947. https://doi.org/10.1016/j. 
neuron.2016.02.024. 
van Os, J., Kapur, S., 2009. Schizophrenia. Lancet 374 (9690), 635–645. 
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